Cargando…

Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World “POWERFUL” Study

The “POWERFUL” multicenter, retrospective, and prospective study investigated the effectiveness of pomalidomide plus low-dose dexamethasone (POM/LoDex) therapy in relapsed/refractory multiple myeloma in routine care in Greece. Ninety-nine eligible adult patients treated with POM/LoDex according to t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terpos, Evangelos, Repousis, Panagiotis, Lalayanni, Chrysavgi, Hatjiharissi, Evdoxia, Assimakopoulou, Theodora, Vassilopoulos, Georgios, Pouli, Anastasia, Spanoudakis, Emmanouil, Michalis, Eurydiki, Pangalis, Gerassimos, Ntanasis-Stathopoulos, Ioannis, Poziopoulos, Christos, Kyrtsonis, Marie-Christine, Pappa, Vasiliki, Symeonidis, Argiris, Georgopoulos, Christos, Zikos, Panagiotis M., Gavriatopoulou, Maria, Papadaki, Helen A., Dadakaridou, Magdalini, Karvounis-Marolachakis, Kiki, Katodritou, Eirini
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038613/ https://www.ncbi.nlm.nih.gov/pubmed/33916376 http://dx.doi.org/10.3390/jcm10071509

Ejemplares similares

Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”
por: Terpos, Evangelos, et al.
Publicado: (2022)

P22: A NON-INTERVENTIONAL, PROSPECTIVE, OBSERVATIONAL STUDY OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH IXAZOMIB IN REAL-WORLD SETTINGS IN GREECE; INTERIM RESULTS OF THE ‘OL-ORAL’ STUDY
por: Katodritou, E, et al.
Publicado: (2022)

P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY
por: Terpos, Evangelos, et al.
Publicado: (2023)

P920: EVALUATION OF EARLY PROGRESSIVE DISEASE (EPD) IN NEWLY DIAGNOSED MYELOMA PATIENTS AND IDENTIFICATION OF PROGNOSTIC FACTORS IN THE ERA OF MODERN THERAPIES. THE GREEK MYELOMA STUDY GROUP EXPERIENCE.
por: Katodritou, Eirini, et al.
Publicado: (2023)

Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study
por: Terpos, Evangelos, et al.
Publicado: (2021)

New Insights into Malignant B-Cell Disorders
por: Kyrtsonis, Marie-Christine, et al.
Publicado: (2015)

P16: DARATUMUMAB MONOTHERAPY HAS A FAVORABLE EFFECT ON BONE METABOLISM IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA; RESULTS OF THE PHASE 2 REBUILD STUDY
por: Terpos, E, et al.
Publicado: (2022)

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival
por: Katodritou, Eirini, et al.
Publicado: (2018)

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
por: Angelopoulou, Maria K., et al.
Publicado: (2017)

P897: EVALUATION OF THE PROGNOSTIC IMPACT OF SECOND LINE ANTI-MYELOMA TREATMENTS ON POST- PROGRESSION OUTCOMES IN THE REAL-WORLD SETTING: THE GREEK MYELOMA STUDY GROUP EXPERIENCE.
por: Katodritou, Eirini, et al.
Publicado: (2023)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

P916: COEXISTENCE OF ≥2 HIGH-RISK MOLECULAR ABNORMALITIES SUPERVENES THE PROGNOSTIC VALUE OF THE REVISED INTERNATIONAL STAGING SYSTEM FOR MYELOMA: REAL-WORLD DATA ANALYSIS FROM THE GREEK MYELOMA STUDY GROUP
por: Katodritou, E., et al.
Publicado: (2022)

Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories
por: Gkoliou, Glykeria, et al.
Publicado: (2023)

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group
por: Katodritou, Eirini, et al.
Publicado: (2018)

Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection
por: Malandrakis, Panagiotis, et al.
Publicado: (2020)

The incidence of myelodysplastic syndromes in Western Greece is increasing
por: Avgerinou, Christina, et al.
Publicado: (2013)

The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5‐azacytidine: Results from the Hellenic 5‐azacytidine registry
por: Diamantopoulos, Panagiotis, et al.
Publicado: (2019)

Population Pharmacokinetics of Pomalidomide
por: Li, Yan, et al.
Publicado: (2015)

Pomalidomide-induced hypothyroidism
por: Ali, Sulaiman Haji, et al.
Publicado: (2017)

Primary gastric non-Hodgkin lymphomas: Recent advances regarding disease pathogenesis and treatment
por: Diamantidis, Michael D, et al.
Publicado: (2021)

Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation
por: Diamantidis, Michael D., et al.
Publicado: (2022)

Outcomes of Patients with Hematologic Malignancies and COVID-19: Perspective of a Large Hematology Center in Greece
por: Spyridis, Nikolaos, et al.
Publicado: (2021)

Pomalidomide for the Treatment of Multiple Myeloma
por: Clark, Stephen M., et al.
Publicado: (2014)

Optimizing Adjuvant Therapy after Surgery for Colorectal Cancer Liver Metastases: A Systematic Review
por: Georgilis, Emmanouil, et al.
Publicado: (2023)

A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma
por: Papanota, Aristea-Maria, et al.
Publicado: (2021)

Risk Factors, Prevalence, and Outcomes of Invasive Fungal Disease Post Hematopoietic Cell Transplantation and Cellular Therapies: A Retrospective Monocenter Real-Life Analysis
por: Gavriilaki, Eleni, et al.
Publicado: (2023)

Spotlight on pomalidomide: could less be more?
por: Zander, T, et al.
Publicado: (2017)

Lung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review
por: Palermos, Dionysios, et al.
Publicado: (2022)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
por: Gowin, Krisstina L, et al.
Publicado: (2015)

Pomalidomide Reduces Ischemic Brain Injury in Rodents
por: Tsai, Yan-Rou, et al.
Publicado: (2019)

Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma
por: Modi, Dipenkumar, et al.
Publicado: (2015)

Olive oil intake and cancer risk: A systematic review and meta-analysis
por: Markellos, Christos, et al.
Publicado: (2022)

P826: THE CIRCULAR RNA OF THE CHAPERONIN-CONTAINING TCP1 SUBUNIT 3 GENE (CIRC-CCT3) IS OVEREXPRESSED IN MULTIPLE MYELOMA AND PREDICTS A FAVORABLE PROGNOSTIC OUTCOME, INDEPENDENTLY OF THE R-ISS STAGING
por: Papatsirou, Maria, et al.
Publicado: (2023)

New drugs in multiple myeloma – role of carfilzomib and pomalidomide
por: Jurczyszyn, Artur, et al.
Publicado: (2014)

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
por: Chanan-Khan, A A, et al.
Publicado: (2013)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

Pomalidomide-induced lung injury: A case report
por: Vivien, Alexandre, et al.
Publicado: (2023)

Bing-Neel Syndrome: Real-Life Experience in Personalized Diagnostic Approach and Treatment
por: Kotsos, Dimitrios, et al.
Publicado: (2022)

Real‐world complication burden and disease management paradigms in transfusion‐related β‐thalassaemia in Greece: Results from ULYSSES, an epidemiological, multicentre, retrospective cross‐sectional study
por: Kattamis, Antonis, et al.
Publicado: (2023)

One Step forward: Benthic Pelagic Coupling and Indicators for Environmental Status
por: Dimitriou, Panagiotis D., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_96atcb145v57gcngar8ve8qvup